Abstract：Objective To investigate the expression of matrix metalloproteinase 9 (MMP9) in the serum of patients with acute myocardial infarction and its prognostic value.Methods Sixty-eight patients with acute myocardial infarction treated with direct coronary intervention in our hospital were selected as the observation group while another 68 healthy volunteers served as the control group. The levels of MMP9 in both groups were detected by ELISA. The patients in the observation group were divided into two groups according to MMP9 levels, with 47 cases in the high MMP9 group and 21 cases in the low MMP9 group, and the incidence of adverse cardiovascular events during follow up was compared between the two groups.Results The serum MMP9 level was (130.93±45.07) μg /L in the control group, much higher than (252.39±82.20) μg /L in the observation group (P<0.05). Logistic regression analysis results showed that MMP9 was one of the independent risk factors for AMI (OR=1.837, P<0.05). ROC analysis results showed that the AUC for MMP9 to predict AMI was 0.901, the optimal operation point was 200.06 μg /L, and the sensitivity and specificity were 0.750 and 0.941 respectively. According to the optimal operation point, patients in the observation group were divided into the high MMP9 group (n=47) and the low MMP9 group (n=21). The rate of adverse cardiovascular events at 6 months, 12 months, 18 months and 24 months after surgery was higher in the high MMP9 group than in the low MMP9 group,especially at 18 months and 24 months after surgery (P<0.05).Conclusions Serum MMP9 is highly expressed in patients with acute myocardial infarction, and MMP9 can be used as a prognostic indicator.
Kuliczkowski W,Urbaniak J,Hallén J,et al. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-eleva-tionmyocardial infarction treated with primary angioplasty [J]. Kardiol Pol,2013,71(5) : 453-463.
Gershlick A H,Khan J N,Kelly D J,et al.Randomized trial of com plete versus lesion only revascularization in patients undergoing primary percutaneous coronary intervention for iand multivessel disease: the Cv lprit trial [J]. J Am Coll Cardiol,2015,65(10) : 963-972.
[6]
刘新宇.基质金属蛋白酶-9、C-反应蛋白及 P 选择素对老年急性心肌梗死患者PCI治疗后效果和预后的评价[J]. 岭南心血管病杂志,2017,23(4) : 381-283.
Ozako Y,Imanishi T,Tanimoto T,et al. Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction [J]. Int Heart J,2014,55(1):17-21.
Vatankulu M A,Bacaksiz A,Sonmez O,et al. Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction [J]. Cardiovasc Ther,2013,31(4):224-229.
Gostiljac D,Dorevi P B,Djuri D,et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome [J]. Acta Physiol Hung,2011,98 (1):91-97.
2019, Vol. 30 
